RU94036778A - Фармацевтические композиции, способы лечения, способ диагностики, способы идентификации, рецепторы, клетки, нуклеиновые кислоты, соединения, антитела, агент связывания рецептора, способ модуляции экспрессии рецептора, способ уничтожения клетки - Google Patents
Фармацевтические композиции, способы лечения, способ диагностики, способы идентификации, рецепторы, клетки, нуклеиновые кислоты, соединения, антитела, агент связывания рецептора, способ модуляции экспрессии рецептора, способ уничтожения клеткиInfo
- Publication number
- RU94036778A RU94036778A RU94036778/14A RU94036778A RU94036778A RU 94036778 A RU94036778 A RU 94036778A RU 94036778/14 A RU94036778/14 A RU 94036778/14A RU 94036778 A RU94036778 A RU 94036778A RU 94036778 A RU94036778 A RU 94036778A
- Authority
- RU
- Russia
- Prior art keywords
- cells
- renal
- receptors
- activity
- agent
- Prior art date
Links
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/70—Carbohydrates; Sugars; Derivatives thereof
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/13—Amines
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/13—Amines
- A61K31/135—Amines having aromatic rings, e.g. ketamine, nortriptyline
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/16—Amides, e.g. hydroxamic acids
- A61K31/165—Amides, e.g. hydroxamic acids having aromatic rings, e.g. colchicine, atenolol, progabide
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/185—Acids; Anhydrides, halides or salts thereof, e.g. sulfur acids, imidic, hydrazonic or hydroximic acids
- A61K31/19—Carboxylic acids, e.g. valproic acid
- A61K31/195—Carboxylic acids, e.g. valproic acid having an amino group
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/21—Esters, e.g. nitroglycerine, selenocyanates
- A61K31/215—Esters, e.g. nitroglycerine, selenocyanates of carboxylic acids
- A61K31/235—Esters, e.g. nitroglycerine, selenocyanates of carboxylic acids having an aromatic ring attached to a carboxyl group
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/275—Nitriles; Isonitriles
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/40—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
- A61K31/415—1,2-Diazoles
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
- A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/55—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having seven-membered rings, e.g. azelastine, pentylenetetrazole
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/02—Nutrients, e.g. vitamins, minerals
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/12—Drugs for disorders of the metabolism for electrolyte homeostasis
- A61P3/14—Drugs for disorders of the metabolism for electrolyte homeostasis for calcium homeostasis
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/12—Antihypertensives
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
- C07K14/705—Receptors; Cell surface antigens; Cell surface determinants
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
- C12N15/09—Recombinant DNA-technology
- C12N15/63—Introduction of foreign genetic material using vectors; Vectors; Use of hosts therefor; Regulation of expression
- C12N15/79—Vectors or expression systems specially adapted for eukaryotic hosts
- C12N15/85—Vectors or expression systems specially adapted for eukaryotic hosts for animal cells
- C12N15/8509—Vectors or expression systems specially adapted for eukaryotic hosts for animal cells for producing genetically modified animals, e.g. transgenic
-
- A—HUMAN NECESSITIES
- A01—AGRICULTURE; FORESTRY; ANIMAL HUSBANDRY; HUNTING; TRAPPING; FISHING
- A01K—ANIMAL HUSBANDRY; CARE OF BIRDS, FISHES, INSECTS; FISHING; REARING OR BREEDING ANIMALS, NOT OTHERWISE PROVIDED FOR; NEW BREEDS OF ANIMALS
- A01K2217/00—Genetically modified animals
- A01K2217/05—Animals comprising random inserted nucleic acids (transgenic)
-
- A—HUMAN NECESSITIES
- A01—AGRICULTURE; FORESTRY; ANIMAL HUSBANDRY; HUNTING; TRAPPING; FISHING
- A01K—ANIMAL HUSBANDRY; CARE OF BIRDS, FISHES, INSECTS; FISHING; REARING OR BREEDING ANIMALS, NOT OTHERWISE PROVIDED FOR; NEW BREEDS OF ANIMALS
- A01K2217/00—Genetically modified animals
- A01K2217/07—Animals genetically altered by homologous recombination
- A01K2217/075—Animals genetically altered by homologous recombination inducing loss of function, i.e. knock out
-
- A—HUMAN NECESSITIES
- A01—AGRICULTURE; FORESTRY; ANIMAL HUSBANDRY; HUNTING; TRAPPING; FISHING
- A01K—ANIMAL HUSBANDRY; CARE OF BIRDS, FISHES, INSECTS; FISHING; REARING OR BREEDING ANIMALS, NOT OTHERWISE PROVIDED FOR; NEW BREEDS OF ANIMALS
- A01K2217/00—Genetically modified animals
- A01K2217/30—Animal model comprising expression system for selective cell killing, e.g. toxins, enzyme dependent prodrug therapy using ganciclovir
-
- A—HUMAN NECESSITIES
- A01—AGRICULTURE; FORESTRY; ANIMAL HUSBANDRY; HUNTING; TRAPPING; FISHING
- A01K—ANIMAL HUSBANDRY; CARE OF BIRDS, FISHES, INSECTS; FISHING; REARING OR BREEDING ANIMALS, NOT OTHERWISE PROVIDED FOR; NEW BREEDS OF ANIMALS
- A01K2227/00—Animals characterised by species
- A01K2227/10—Mammal
-
- A—HUMAN NECESSITIES
- A01—AGRICULTURE; FORESTRY; ANIMAL HUSBANDRY; HUNTING; TRAPPING; FISHING
- A01K—ANIMAL HUSBANDRY; CARE OF BIRDS, FISHES, INSECTS; FISHING; REARING OR BREEDING ANIMALS, NOT OTHERWISE PROVIDED FOR; NEW BREEDS OF ANIMALS
- A01K2267/00—Animals characterised by purpose
- A01K2267/03—Animal model, e.g. for test or diseases
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2319/00—Fusion polypeptide
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Chemical & Material Sciences (AREA)
- General Health & Medical Sciences (AREA)
- Veterinary Medicine (AREA)
- Medicinal Chemistry (AREA)
- Animal Behavior & Ethology (AREA)
- Public Health (AREA)
- Pharmacology & Pharmacy (AREA)
- Epidemiology (AREA)
- Organic Chemistry (AREA)
- Engineering & Computer Science (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- General Chemical & Material Sciences (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Genetics & Genomics (AREA)
- Zoology (AREA)
- Molecular Biology (AREA)
- Hematology (AREA)
- Obesity (AREA)
- Diabetes (AREA)
- Wood Science & Technology (AREA)
- General Engineering & Computer Science (AREA)
- Biotechnology (AREA)
- Biomedical Technology (AREA)
- Biochemistry (AREA)
- Biophysics (AREA)
- Gastroenterology & Hepatology (AREA)
- Rheumatology (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Physics & Mathematics (AREA)
- Heart & Thoracic Surgery (AREA)
- Toxicology (AREA)
- Immunology (AREA)
- Plant Pathology (AREA)
- Microbiology (AREA)
- Cell Biology (AREA)
- Endocrinology (AREA)
- Cardiology (AREA)
Abstract
Способ и композиция, полезные для лечения пациента, имеющего заболевание, характеризующееся аномальным уровнем одного или более компонентов, активность которых регулируется или влияет на активность одного или более рецепторов неорганических ионов. Новые соединения, полезные в этих способах и композициях, также приводятся. Способ включает введение пациенту терапевтически эффективного количества молекулы, активной по отношению к одному или более рецепторам неорганических ионов, в качестве агента или антагониста. Предпочтительно молекула способна воздействовать как или селективный агонист или антагонист на Са<M^>2+<D> рецептор одной или более, но не всех клеток, выбранных в группе, состоящей из паратироидных клеток, костных остеокластов, окологломерулярных почечных клеток, проксимальных канальцевых почечных клеток, периферических канальцевых почечных клеток, клеток толстой восходящей ветви петли Хенля и/или собирающей протоки, кератиноцита в эпидермисе, парафолликулярной клетки в тироиде (С-клеток), интестинальных клеток, трофобласта в плаценте, тромбоцита, клетки сосудов гладкой мышцы, клетки сердечного предсердия, клеток, секретирующих гастрин и глюкагон, почечной мезангиальной клетки и клетки грудной железы.
Claims (1)
- Способ и композиция, полезные для лечения пациента, имеющего заболевание, характеризующееся аномальным уровнем одного или более компонентов, активность которых регулируется или влияет на активность одного или более рецепторов неорганических ионов. Новые соединения, полезные в этих способах и композициях, также приводятся. Способ включает введение пациенту терапевтически эффективного количества молекулы, активной по отношению к одному или более рецепторам неорганических ионов, в качестве агента или антагониста. Предпочтительно молекула способна воздействовать как или селективный агонист или антагонист на Са<M^>2+<D> рецептор одной или более, но не всех клеток, выбранных в группе, состоящей из паратироидных клеток, костных остеокластов, окологломерулярных почечных клеток, проксимальных канальцевых почечных клеток, периферических канальцевых почечных клеток, клеток толстой восходящей ветви петли Хенля и/или собирающей протоки, кератиноцита в эпидермисе, парафолликулярной клетки в тироиде (С-клеток), интестинальных клеток, трофобласта в плаценте, тромбоцита, клетки сосудов гладкой мышцы, клетки сердечного предсердия, клеток, секретирующих гастрин и глюкагон, почечной мезангиальной клетки и клетки грудной железы.
Applications Claiming Priority (2)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
US07/934161 | 1992-08-21 | ||
PCT/US1993/001642 WO1994018959A1 (en) | 1993-02-23 | 1993-02-23 | Calcium receptor-active molecules |
Publications (2)
Publication Number | Publication Date |
---|---|
RU94036778A true RU94036778A (ru) | 1996-05-20 |
RU2146132C1 RU2146132C1 (ru) | 2000-03-10 |
Family
ID=22236351
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
RU94036778A RU2146132C1 (ru) | 1993-02-23 | 1993-02-23 | Фармацевтическая композиция, активная в отношении рецептора кальция, способ лечения пациента, способ анализа соединения оказывать влияние на активность рецептора неорганического иона, нуклеиновая кислота, кодирующая рецептор, рецептор кальция |
Country Status (9)
Country | Link |
---|---|
EP (1) | EP0637237B1 (ru) |
JP (1) | JP4143118B2 (ru) |
KR (1) | KR100296899B1 (ru) |
AT (1) | ATE267009T1 (ru) |
AU (1) | AU3777093A (ru) |
DE (1) | DE69333527T2 (ru) |
HK (1) | HK1012560A1 (ru) |
RU (1) | RU2146132C1 (ru) |
WO (1) | WO1994018959A1 (ru) |
Cited By (3)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
RU2610661C2 (ru) * | 2010-04-09 | 2017-02-14 | Курна, Инк. | Лечение заболеваний, связанных с фактором роста фибробластов 21 (fgf21), путем ингибирования природного антисмыслового транскрипта к fgf21 |
RU2611187C2 (ru) * | 2010-01-04 | 2017-02-21 | Курна, Инк. | Лечение заболеваний, связанных с интерферон-регуляторным фактором 8 (irf8), путем ингибирования природного антисмыслового транскрипта к irf8 |
RU2619185C2 (ru) * | 2009-12-23 | 2017-05-12 | Курна, Инк. | Лечение заболеваний, связанных с разобщающим белком 2 (ucp2), путем ингибирования природного антисмыслового транскрипта к ucp2 |
Families Citing this family (64)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US5763569A (en) * | 1991-08-23 | 1998-06-09 | The Brigham And Women's Hospital, Inc | Calcium receptor-active molecules |
CA2173747C (en) * | 1991-08-23 | 2006-05-23 | Edward F. Nemeth | Calcium receptor-active arylalkyl amines |
US6313146B1 (en) | 1991-08-23 | 2001-11-06 | Nps Pharmaceuticals, Inc. | Calcium receptor-active molecules |
US5858684A (en) * | 1991-08-23 | 1999-01-12 | The Brigham And Women's Hospital, Inc. | Method of screening calcium receptor-active molecules |
US5688938A (en) * | 1991-08-23 | 1997-11-18 | The Brigham & Women's Hospital, Inc. | Calcium receptor-active molecules |
US6031003A (en) * | 1991-08-23 | 2000-02-29 | Nps Pharmaceuticals, Inc. | Calcium receptor-active molecules |
US5962314A (en) * | 1993-02-23 | 1999-10-05 | Nps Pharmaceuticals, Inc. | Calcium receptor-active molecules |
US5852041A (en) * | 1993-04-07 | 1998-12-22 | Sibia Neurosciences, Inc. | Substituted pyridines useful as modulators of acethylcholine receptors |
DE122005000033I2 (de) | 1994-10-21 | 2006-11-23 | Nps Pharma Inc | Kalzium-Receptor aktive Verbindungen |
US5824550A (en) * | 1994-10-28 | 1998-10-20 | Barnes-Jewish Hopital | Voltage-gated calcium channel and antisense oligonucleotides thereto |
US6060604A (en) * | 1995-03-31 | 2000-05-09 | Florida State University | Pharmaceutical compounds comprising polyamines substituted with electron-affinic groups |
US5585388A (en) * | 1995-04-07 | 1996-12-17 | Sibia Neurosciences, Inc. | Substituted pyridines useful as modulators of acetylcholine receptors |
ES2308779T3 (es) * | 1995-07-26 | 2008-12-01 | Astrazeneca Ab | Receptores quimericos y metodos para identificar compuestos activos en los receptores de glutamato metabotropico y el uso de tales compuestos en el tratamiento de trastornos y enfermedades neurologicas. |
US5794887A (en) | 1995-11-17 | 1998-08-18 | Komerath; Narayanan M. | Stagnation point vortex controller |
US6818660B2 (en) | 1996-04-09 | 2004-11-16 | Nps Pharmaceuticals, Inc. | Calcilytic compounds |
EA002984B1 (ru) * | 1996-04-09 | 2002-12-26 | Эн Пи Эс Фармасьютикалз, Инк. | Кальцилитические соединения, фармацевтические композиции и способ скрининга кальцилитических соединений |
EP1770083B1 (en) * | 1996-05-01 | 2009-04-29 | Nps Pharmaceuticals, Inc. | Inorganic ion receptor-active compounds |
PT907631E (pt) | 1996-05-01 | 2003-10-31 | Nps Pharma Inc | Compostos inorganicos activos como receptores de ioes |
AU3146797A (en) | 1996-05-16 | 1997-12-05 | Board Of Regents, The University Of Texas System | Methods of identifying modulators of perivascular sensory nerve ca2+ receptors |
WO1998001417A1 (fr) | 1996-07-08 | 1998-01-15 | Kirin Beer Kabushiki Kaisha | Composes actifs comme recepteurs du calcium |
US7202261B2 (en) | 1996-12-03 | 2007-04-10 | Nps Pharmaceuticals, Inc. | Calcilytic compounds |
TW483881B (en) | 1996-12-03 | 2002-04-21 | Nps Pharma Inc | Calcilytic compounds |
US6083480A (en) | 1997-05-01 | 2000-07-04 | Diatide, Inc. | Calcitonin receptor binding reagents |
WO1999038500A2 (en) * | 1998-01-30 | 1999-08-05 | The Brigham And Women's Hospital, Inc. | The human calcium-sensing receptor in the detection and treatment of cancer |
JP2002527414A (ja) | 1998-10-14 | 2002-08-27 | オーソ−マクニール・フアーマシユーチカル・インコーポレーテツド | 1,2−ジ置換シクロプロパン |
DE19924148A1 (de) * | 1999-05-26 | 2000-12-07 | Univ Heidelberg | Sphingomyelinasehemmer |
US7176322B2 (en) | 2002-05-23 | 2007-02-13 | Amgen Inc. | Calcium receptor modulating agents |
US6908935B2 (en) | 2002-05-23 | 2005-06-21 | Amgen Inc. | Calcium receptor modulating agents |
US20040081970A1 (en) * | 2002-10-28 | 2004-04-29 | Athersys, Inc. | Calcium-sensing receptor 2 (CaR2) and methods for using |
US7105537B2 (en) | 2003-01-28 | 2006-09-12 | Bristol-Myers Squibb Company | 2-substituted cyclic amines as calcium sensing receptor modulators |
US7205322B2 (en) | 2003-02-12 | 2007-04-17 | Bristol-Myers Squibb Company | Thiazolidine compounds as calcium sensing receptor modulators |
US7265145B2 (en) | 2003-05-28 | 2007-09-04 | Bristol-Myers Squibb Company | Substituted piperidines and pyrrolidines as calcium sensing receptor modulators and method |
DK2821067T3 (en) | 2003-09-12 | 2017-12-04 | Amgen Inc | Quick solution formulation of cinacalcet |
WO2005065050A2 (ja) | 2003-12-25 | 2005-07-21 | Asahi Kasei Pharma Corporation | 2環化合物 |
JP4629036B2 (ja) | 2004-05-28 | 2011-02-09 | 田辺三菱製薬株式会社 | アリールアルキルアミン化合物及びその製法 |
US7361789B1 (en) | 2004-07-28 | 2008-04-22 | Amgen Inc. | Dihydronaphthalene compounds, compositions, uses thereof, and methods for synthesis |
ES2527058T3 (es) | 2005-05-19 | 2015-01-20 | Astellas Pharma Inc. | Derivado de pirrolidina o sus sales |
CA2620469C (en) | 2005-09-02 | 2014-04-01 | Amgen Inc. | Methods of modulating intestinal fluid balance |
WO2007055388A2 (en) * | 2005-11-09 | 2007-05-18 | Ajinomoto Co., Inc. | Calcium receptor activator |
CA2645494C (en) | 2006-03-23 | 2016-01-12 | Amgen Inc. | Methods and compositions for making and using polymorphs of cinacalcet |
CN101437490A (zh) | 2006-04-20 | 2009-05-20 | 安美基公司 | 稳定乳液配方 |
US8153658B2 (en) | 2006-11-16 | 2012-04-10 | Astellas Pharma, Inc. | Piperidine derivative or salt thereof |
AU2008233088B2 (en) | 2007-03-30 | 2013-09-26 | Amgen Inc. | Calcimimetic compounds for use in the treatment of bowel disorders |
EP2212284B1 (en) * | 2007-10-15 | 2014-04-30 | Amgen Inc. | Calcium receptor modulating agents |
EP2225226B1 (en) | 2007-12-26 | 2016-08-17 | Critical Outcome Technologies, Inc. | Compounds and their use in a method for treatment of cancer |
EP2113257A1 (en) * | 2008-04-30 | 2009-11-04 | Consorzio per il Centro di Biomedica Moleculare Scrl | Polyelectrolyte with positive net charge for use as medicament and diagnostic for cancer |
CA2730890C (en) | 2008-07-17 | 2018-05-15 | Critical Outcome Technologies Inc. | Thiosemicarbazone inhibitor compounds and cancer treatment methods |
ES2332636B1 (es) * | 2008-08-06 | 2011-02-10 | Universitat De Les Illes Balears | Composicion de liquido de dialisis. |
JP5551597B2 (ja) | 2008-08-22 | 2014-07-16 | 第一三共株式会社 | シクロアルキルアミン誘導体 |
WO2010103429A1 (en) | 2009-03-10 | 2010-09-16 | Pfizer Inc. | 1,1-(Dimethyl-Ethylamino)-2-Hydroxy-Propoxy]-Ethyl}-3-Methyl-Biphenyl-4- Carboxylic Acid Derivatives As Calcium Receptor Antagonists |
WO2010104882A1 (en) | 2009-03-10 | 2010-09-16 | Amgen Inc. | Methods of modulating sperm motility |
JP2012528086A (ja) | 2009-05-27 | 2012-11-12 | レオ ファーマ アクティーゼルスカブ | 新規のカルシウム感知受容体調節化合物およびその医薬用途 |
EP2435400A2 (en) | 2009-05-27 | 2012-04-04 | Leo Pharma A/S | Novel calcium sensing receptor modulating compounds and pharmaceutical use thereof |
WO2010150837A1 (ja) * | 2009-06-25 | 2010-12-29 | 第一三共株式会社 | インドリン誘導体 |
EP3235818A3 (en) | 2010-04-01 | 2018-03-14 | Critical Outcome Technologies, Inc. | Compounds for the treatment of hiv |
CN102958907A (zh) | 2010-06-30 | 2013-03-06 | 利奥制药有限公司 | 钙敏感受体激动化合物的新多晶型 |
JP5968881B2 (ja) | 2010-06-30 | 2016-08-10 | レオ ファーマ アクティーゼルスカブ | カルシウム模倣化合物の新規多形 |
RU2013128981A (ru) | 2010-11-26 | 2015-01-10 | Лео Фарма А/С | Соединения, активные в отношении чувствительных к кальцию рецепторов |
WO2012069421A1 (en) | 2010-11-26 | 2012-05-31 | Leo Pharma A/S | Calcium-sensing receptor-active compounds |
US20130261132A1 (en) | 2010-11-26 | 2013-10-03 | Leo Pharma A/S | Calcium-sensing receptor-active compounds |
EP2643298A1 (en) | 2010-11-26 | 2013-10-02 | Leo Pharma A/S | Substituted cyclopentyl - azines as casr- active compounds |
EP2705830A1 (en) * | 2012-09-05 | 2014-03-12 | Laboratoire In'Oya SAS | Use of spider venoms for skin whitening/depigmentating and composition comprising spider venoms derivatives |
GB201217330D0 (en) | 2012-09-28 | 2012-11-14 | Univ Cardiff | Therapeutic for treating inflammatory lung disorders |
RU2552300C2 (ru) * | 2013-10-23 | 2015-06-10 | Государственное бюджетное учреждение высшего профессионального образования "Северо-Осетинская государственная медицинская академия" Минздрава Российской Федерации | Способ коррекции состояния костной ткани и профилактики возникновения переломов у больных с сердечно-сосудистыми заболеваниями |
Family Cites Families (6)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US4591605A (en) * | 1981-11-10 | 1986-05-27 | Research Foundation Of State University Of New York | Method and ingestible formulation for inhibiting the secretion of stomach acid |
HU200591B (en) * | 1986-07-11 | 1990-07-28 | Chinoin Gyogyszer Es Vegyeszet | Process for producing new diphenyl propylamine derivatives and pharmaceutical compositions comprising such compounds |
DD298412A5 (de) * | 1989-04-28 | 1992-02-20 | ������@���Kk�� | Verfahren zur herstellung von polypeptiden, die geeignet sind als antagonisten exzitatorischer aminosaeure-neurotransmitter und/oder blocker der calciumkanaele |
CA2062810A1 (en) * | 1989-07-03 | 1991-01-04 | Bruce D. Cherksey | Use of polyamines as ionic-channel regulating agents |
US5312928A (en) * | 1991-02-11 | 1994-05-17 | Cambridge Neuroscience | Calcium channel antagonists and methodology for their identification |
ATE312347T1 (de) * | 1991-08-23 | 2005-12-15 | Nps Pharma Inc | Screening-verfahren für kalzium-rezeptor aktive verbindungen |
-
1993
- 1993-02-23 AT AT93907015T patent/ATE267009T1/de not_active IP Right Cessation
- 1993-02-23 RU RU94036778A patent/RU2146132C1/ru active Protection Beyond IP Right Term
- 1993-02-23 AU AU37770/93A patent/AU3777093A/en not_active Abandoned
- 1993-02-23 EP EP93907015A patent/EP0637237B1/en not_active Expired - Lifetime
- 1993-02-23 JP JP50994894A patent/JP4143118B2/ja not_active Expired - Lifetime
- 1993-02-23 KR KR1019940701319A patent/KR100296899B1/ko not_active IP Right Cessation
- 1993-02-23 WO PCT/US1993/001642 patent/WO1994018959A1/en active IP Right Grant
- 1993-02-23 DE DE69333527T patent/DE69333527T2/de not_active Expired - Lifetime
-
1998
- 1998-12-17 HK HK98113873A patent/HK1012560A1/xx not_active IP Right Cessation
Cited By (3)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
RU2619185C2 (ru) * | 2009-12-23 | 2017-05-12 | Курна, Инк. | Лечение заболеваний, связанных с разобщающим белком 2 (ucp2), путем ингибирования природного антисмыслового транскрипта к ucp2 |
RU2611187C2 (ru) * | 2010-01-04 | 2017-02-21 | Курна, Инк. | Лечение заболеваний, связанных с интерферон-регуляторным фактором 8 (irf8), путем ингибирования природного антисмыслового транскрипта к irf8 |
RU2610661C2 (ru) * | 2010-04-09 | 2017-02-14 | Курна, Инк. | Лечение заболеваний, связанных с фактором роста фибробластов 21 (fgf21), путем ингибирования природного антисмыслового транскрипта к fgf21 |
Also Published As
Publication number | Publication date |
---|---|
AU3777093A (en) | 1994-09-14 |
HK1012560A1 (en) | 1999-08-06 |
EP0637237B1 (en) | 2004-05-19 |
KR100296899B1 (ko) | 2001-10-24 |
JPH07506380A (ja) | 1995-07-13 |
JP4143118B2 (ja) | 2008-09-03 |
WO1994018959A1 (en) | 1994-09-01 |
ATE267009T1 (de) | 2004-06-15 |
EP0637237A1 (en) | 1995-02-08 |
DE69333527T2 (de) | 2005-06-16 |
RU2146132C1 (ru) | 2000-03-10 |
DE69333527D1 (de) | 2004-06-24 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
RU94036778A (ru) | Фармацевтические композиции, способы лечения, способ диагностики, способы идентификации, рецепторы, клетки, нуклеиновые кислоты, соединения, антитела, агент связывания рецептора, способ модуляции экспрессии рецептора, способ уничтожения клетки | |
Mahgoub | Medical management of mycetoma. | |
Toh et al. | The infected nonunion of the tibia. | |
AU596954B2 (en) | Wound healing agents | |
Llovera et al. | Anti-TNF treatment reverts increased muscle ubiquitin gene expression in tumour-bearing rats | |
DE60121355T2 (de) | Absorptionsverbesserer | |
CA2363067A1 (en) | Compounds and methods to inhibit or augment an inflammatory response | |
BG64350B1 (bg) | Универсално приложима кръвна плазма | |
WO2004051280A2 (de) | Bestimmung agonistischer autoantikörper | |
EP1597271A2 (de) | Peptide gegen kälteunverträglichkeit hervorrufende autoantikörper und ihre verwendung | |
Rutten et al. | Postoperative course of plasma protein binding of lignocaine, ropivacaine and bupivacaine in sheep | |
WO1996035447A1 (en) | Pharmaceutical administration form of parathyroid hormone having an active ingredient release period of from two to six hours | |
US20210023140A1 (en) | Platelet formulations and medical uses thereof | |
Cannon et al. | The stimulation of adrenal secretion by emotional excitement | |
Perkins et al. | Distal‐proximal nerve implants in spinal cord transection | |
RU2005430C1 (ru) | Способ лечения остеомиелита нижних конечностей | |
Dorrestein et al. | Tissue distribution of amoxycillin after oral and intramuscular administration to pigeons (Columba livia) | |
DE10327066A1 (de) | Bestimmung agonistischer Autoantikörper | |
Gershbein et al. | Action of drugs and chemical agents on rat liver regeneration | |
Bisgaard | Further Contributions to the Problem of the Function of the Parathyroid Glands and the Pathogenesis of true Epilepsy | |
JPS61238726A (ja) | 細胞賦活剤 | |
RU2136277C1 (ru) | Фармацевтическая композиция | |
SU1174966A1 (ru) | Способ моделировани осложненного инфаркта миокарда | |
RU2127548C1 (ru) | Способ коронарографии в эксперименте | |
Kinova et al. | Takotsubo syndrome after bone cement injection during hip replacement |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
ND4A | Extension of patent duration |
Free format text: CLAIMS: 1, 2, 5-13, 15-17 |